Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Interim Management Statement

18 Nov 2011 07:00

RNS Number : 3240S
Evolution Group PLC
18 November 2011
 



Embargoed until 7.00am 18 Nov 2011

 

The Evolution Group Plc

(the "Evolution Group", the "Group", the "Company")

Interim Management Statement

 

Evolution Group, the listed investment bank and private client investment management group, today announces its second Interim Management Statement for the financial year ending 31 December 2011, as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3. This relates to the period from 1 July 2011 to today's date.

 

Investec Offer

 

As announced on 27th October 2011, the Group's shareholders voted by the requisite majority to approve Investec plc's acquisition of the Group. The hearing of the petition to the Court to sanction the Court sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme") and to confirm the related Capital Reduction is expected to take place on 13 December 2011, although this is dependent on certain conditions to the Scheme having been satisfied by that date, including the receipt of requisite regulatory and anti-trust clearances.

 

Subject to the Court sanctioning the Scheme and the satisfaction of certain other outstanding conditions, it is expected that the last day for dealings in Evolution Shares will be 13 December 2011 and the Scheme will become effective on 14 December 2011. If the Scheme becomes effective on 14 December 2011, it is expected that the new Investec plc shares to be allotted to existing Evolution Group shareholders pursuant to the Scheme will be admitted to the official list of the UK Listing Authority and to trading on the London Stock Exchange's Main Market for listed securities on the 14 December 2011 and the listing of Evolution will be cancelled on 14 December 2011.

 

Group performance

 

Despite ongoing tough market conditions, we are pleased to announce that the Group is line to meet the Board's expectations regarding trading performance.

 

Private Clients1

 

As announced on the 20 October 2011, Williams de Broë completed the acquisition of BNP Paribas Private Investment Management Limited from BNP Paribas Wealth Management S.A.

 

Although still in its infancy the acquisition is proceeding smoothly, bringing £1.5bn of new Assets under Management to the business.

 

Our Private client business also continued to see momentum in organic new fund sales, with Q3 gross inflows of £96m (Q3 2010: £95m), whilst also continuing to attract high calibre professionals to its investment management and business development teams.

 

As a result of these organic and inorganic inflows offsetting recent market falls Assets under Management have grown to be £7.1bn at the end of October 2011, up 18% from £6.0bn at 30 June 2011. We believe this increase in Assets under Management, combined with a scalable business model, leaves Williams de Broë well placed to further increase its profits and margins.

 

Investment Banking2

 

Our Investment Banking division has been significantly impacted by the recent turbulent market conditions and the inherent uncertainty over the Group's future following Investec's initial offer on the 3 August.

 

As a result of these two factors, income is considerably down in Q3, resulting in the business accruing a year to date loss at the adjusted operating level.

 

Due to the current depressed levels of income within the business, Management has taken action to reduce the cost base from Q4 onwards. This has been achieved by reducing headcount by 60 employees and continuing to have a disciplined approach to all areas of discretionary expenditure.

 

Despite these recent losses, the corporate finance and debt capital markets ("DCM") pipelines remain strong, including seven IPOs, six further retail bond mandates and a number of secondary equity raisings expected to complete before the year end.

 

To date in 2011, the investment banking division has acted on 10 equity capital market transactions, with a total of £1.4bn raised by its clients. Our DCM business has completed three mandates during the period, notably including Tesco Bank (raising £125m), Places for People (the first social housing retail bond issue, raising £145m) and National Grid (the first RPI-linked retail bond, raising £282.5m).

 

 

Notes

1The results of Private Clients are defined as those arising from Williams de Broë Limited, WDB Asset Management Limited, WDB AssetMaster Management Company Limited and from Williams de Broë Private Investment Management Limited (Formally BNP Paribas Private Investment Management Limited).

2The results of Investment Banking are defined as those arising from Evolution Securities Limited, its subsidiary Evolution Securities (US) Inc. ("ESUS") and Darwin Strategic Limited ("Darwin").

 

Forward looking statements

 

This interim management statement may contain forward-looking statements with respect to the financial condition, results, operations and businesses of The Evolution Group Plc. Such statements and forecasts involve risk and uncertainty because they relate to events and depend upon circumstances that will occur in the future. There are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by forward-looking statements and forecasts. Forward-looking statements and forecasts are based on the Directors' current view and information known to them at the date of this statement. The Directors do not make any undertaking to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Nothing in this interim management statement should be construed as a profit forecast.

 

-Ends-

 

For further information, please contact:

 

The Evolution Group Plc

Alex Snow, Chief Executive Officer

 

020 7071 4300

 

 

Pelham Bell Pottinger (Financial PR to Investec)

020 7861 3925

Victoria Geoghegan

 

 

Notes to Editors:

 

The Evolution Group Plc

The Evolution Group is the holding company of Evolution Securities Limited, Williams de Broë Limited and Evolution Securities China Limited. Founded in April 2001 and originally listed on AIM, the Evolution Group joined the LSE Official List in 2003; the Group currently has a market capitalisation of approximately £180 million.

 

Evolution Securities Limited is a leading investment bank focused on UK mid cap public companies. It provides a full range of investment banking services including equity research, institutional sales and trading, market making and corporate finance advice. Evolution Securities Limited has over 70 retained corporate clients. It is authorised and regulated by the Financial Services Authority.

 

Williams de Broë Limited is one of the UK's leading and fastest growing private client investment managers, with offices in Bath, Birmingham, Bournemouth, Edinburgh, Exeter, Guildford and London. Williams de Broë Limited is authorised and regulated by the Financial Services Authority.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSFMMMMVNVGMZM
Date   Source Headline
28th Mar 20197:00 amRNSPoster presentation of Imperial College data
25th Mar 20197:00 amRNSSFX-01 meets primary endpoints in STEM trial
18th Mar 20192:01 pmRNSPrice Monitoring Extension
18th Mar 20197:00 amRNSUpdate on SFX-01 trial read-out dates
5th Mar 20197:00 amRNSSFX-01 data published in peer reviewed journal
6th Feb 20193:30 pmRNSHolding(s) in Company
5th Feb 20197:00 amRNSClinical trial update confirms read-outs on track
30th Jan 20195:28 pmRNSGrant of Options
23rd Jan 20197:00 amRNSSFX-01 featured in Nature Reviews Drug Discovery
22nd Jan 20197:00 amRNSChange of Adviser
19th Dec 20186:02 pmRNSShare option exercise and issue of equity
12th Dec 20187:00 amRNSInterim Results
10th Dec 20183:00 pmRNSNominated Adviser Status
4th Dec 20187:00 amRNSPoster Presentation of SFX-01 and Trial Update
3rd Dec 20187:00 amRNSNotification of Half Year Results
19th Nov 20187:00 amRNSInvestor Presentation in Manchester
8th Nov 20187:00 amRNSDirectorate Changes
23rd Oct 20189:57 amRNSHolding(s) in Company
18th Oct 20187:00 amRNSPlacing
18th Sep 20187:00 amRNSInvestor Symposium
11th Sep 20187:00 amRNSNotice of Investor Symposium
26th Jul 20183:22 pmRNSResult of AGM
26th Jul 20187:00 amRNSAGM Statement
25th Jul 20187:00 amRNSFinal Patient Recruited in STEM Phase IIa Trial
10th Jul 201811:00 amRNSGrant of share options, issue of equity and TVR
29th Jun 201810:45 amEQSHardman & Co Research: Evgen Pharma (EVG): 2018, a pivotal year
21st Jun 201812:30 pmRNSPosting of Annual Report and AGM Notice
13th Jun 20182:15 pmEQSHardman & Co Research: Evgen Pharma (EVG): Encouraging interim data from the STEM trial
13th Jun 20187:00 amRNSFull Year Results
11th Jun 20189:05 amRNSSecond Price Monitoring Extn
11th Jun 20189:00 amRNSPrice Monitoring Extension
11th Jun 20187:00 amRNSInterim Update on STEM Trial
7th Jun 20184:40 pmRNSSecond Price Monitoring Extn
7th Jun 20184:35 pmRNSPrice Monitoring Extension
30th May 20187:00 amRNSNotification of Preliminary Results
15th May 201811:00 amRNSPrice Monitoring Extension
14th May 20187:00 amRNSUpcoming Investor Presentations
2nd May 20187:00 amRNSGrant of further European patent
26th Apr 20184:40 pmRNSSecond Price Monitoring Extn
26th Apr 20184:35 pmRNSPrice Monitoring Extension
24th Apr 20187:00 amRNSPresentation at World Orphan Drug Congress USA
20th Mar 20187:00 amRNSResearch Collaboration with Imperial College
5th Mar 20187:00 amRNSUpdate on Novel Sulforaphane Analogues
15th Jan 20187:00 amRNSPoster Presentation of SFX-01 Mechanistic Data
10th Jan 20184:31 pmRNSNotification of Major Interest in Shares
5th Jan 20189:49 amRNSNotification of Major Interest in Shares
5th Jan 20189:48 amRNSNotification of Major Interest in Shares
2nd Jan 20185:44 pmRNSTotal Voting Rights
28th Dec 201711:49 amRNSResult of General Meeting
22nd Dec 201710:10 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.